K. Chung (London, United Kingdom), K. Rabe (Grosshansdorf, Germany)
Tiotropium bromide: Efficacy and safety in complex treatment of COPD M. Kulynych-Miskiv (Galych, Ukraine)
| |
A randomized placebo and active controlled trial of AZD8871 a novel dual acting bronchodilator in COPD patients D. Singh (Manchester, United Kingdom)
| |
Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma S. Jabbal (Dundee, United Kingdom)
| |
Smart Watch-based Coaching with Tiotropium and Olodaterol Ameliorates Physical Activity in Chronic Obstructive Pulmonary Disease Patients E. Gabazza (Tsu-Mie, Japan)
| |
Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) in patients with moderate COPD: Results from the CRYSTAL study T. Greulich (Marburg, Germany)
| |
Delayed time to first and subsequent exacerbations independent of season with indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone (SFC): the FLAME study K. Chapman (Toronto, ON, Canada)
| |
Indacaterol/glycopyrronium (IND/GLY) reduces days with COPD exacerbation vs salmeterol/fluticasone (SFC) independent of PRO tool: results of the FLAME study J. Wedzicha (London, United Kingdom)
| |
Bronchoprotective activity and safety evaluation of the novel antimuscarinic/ß2 agonist (MABA) CHF6366 in dogs C. Carnini (Parma, Pr, Italy)
| |
In vitro pharmacological characterization of the novel inhaled bronchodilator CHF6366 acting as dual muscarinic antagonist/ß2-agonist (MABA) F. Pastore (PARMA (PR), Italy)
| |
Contractile effects of NaV1.5 current in rabbit bronchial smooth muscle. k. Thornbury (Dundalk, Ireland)
| |
N-Acetylcysteine protects human bronchi via inhibiting neurokinin A L. Calzetta (Roma, Rm, Italy)
| |
The impact of tiotropium for exercise induced bronchoconstriction K. Terada (Himeji city, Japan)
| |
Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial C. Wong (Auckland, New Zealand)
| |
Interaction between tiotropium bromide and olodaterol in human bronchial smooth muscle M. Cazzola (Roma, Rm, Italy)
| |
A randomized placebo controlled trial of AZD8871 a novel dual acting bronchodilator in asthmatics. E. Jimenez Lozano (Barcelona, Spain)
| |
Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD G. Ferguson (Farmington Hills, United States of America)
| |
One year change in health status in patients with stable Chronic Obstructive Pulmonary Disease (COPD) under long-acting bronchodilators treatment C. Wang (Beijing, China)
| |
Clinical synergism of LABA/LAMA combinations in COPD patients P. Rogliani (Roma, Rm, Italy)
| |